ISDX to AIM move for Venn Life Sciences

Venn Life Sciences has joined the Alternative Investment Market and raised growth funds to support the move.

Following an announcement in November that Venn Life Sciences was to join London’s Junior Market, the clinical trial business has completed its listing.

In doing so it has raised £2.5 million through the issue of 8,333,333 new ordinary shares at 30 pence each from institutional investors.

Venn Life Sciences is a clinical research organisation which provides consulting and clinical trial services to pharmaceutical, biotechnology and medical device companies. It has its main bases in France, the Netherlands and Ireland and a branch office in Switzerland.

Prior to joining AIM, it was listed on the ICAP Securities & Derivatives Exchange – a platform which used to be PLUS-SX.

Tony Richardson, proposed CEO of Venn Life Sciences, comments, ‘Moving to AIM is the first step in our strategy to build a mid-sized pan-European CRO.

‘We expect to achieve this through organic growth but also by targeting the acquisition of smaller, profitable regional European CRO’s to complement our existing geographies.’

Hunter Ruthven

Hunter Ruthven

Hunter was the Editor for from 2012 to 2014, before moving on to Caspian Media Ltd to be Editor of Real Business.

Related Topics

Early Stage Funding